Palladia
بالاديا
Palladia (toceranib phosphate) is an oral multi-kinase inhibitor antineoplastic agent (receptor tyrosine kinase inhibitor) indicated for the treatment of Patnaik higher-grade (Grade II or III) recurrent or non-resectable cutaneous mast cell tumors with or without regional lymph node involvement in dogs.
Dosage Form
Tablet
Product Type
Pharmaceutical
Manufacturer
Package
Bottles of 30 round, film-coated tablets in 10 mg (blue), 15 mg (orange), and 50 mg (red) strengths
Dosages
| Species | Dosage | Route | Duration |
|---|---|---|---|
| Dog | 3.25 mg toceranib/kg body weight every other day | Oral (PO) | Administer every other day; dose adjustments based on clinical monitoring |
Withdrawal Periods
No withdrawal information available.
Indications
-
Treatment of recurrent or non-resectable Grade II or Grade III cutaneous mast cell tumors in dogs with or without regional lymph node involvement.
Contraindications
-
Do not use in dogs less than 24 months of age or weighing less than 5 kg.
-
Do not use in pregnant, lactating, or breeding dogs.
Precautions
-
Toceranib can cause vascular and gastrointestinal toxicity, including GI perforation, pancreatitis, and proteinuria.
-
Routine hematology, serum biochemistry, and urinalysis (urine protein:creatinine ratio) are required before and during treatment.
-
Gloves must be worn when administering tablets or handling feces/urine of treated dogs.
Side Effects
-
Diarrhea, anorexia, vomiting, lethargy, weight loss, neutropenia, cutaneous depigmentation, and lameness/muscle cramping.
Images
Documents
-
Download
Palladia Prescribing Information
Leaflet
Active Ingredients
Diseases
No diseases linked.
Related Products
No data available
Information has not been added yet.
Related Products By Active Ingredient
No data available
Information has not been added yet.
Companies
-
Zoetis
Manufacturer
Alternatives
No alternatives available.